HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serologic differentiation of human T lymphotropic virus type I from type II infection by synthetic peptide immunoassays.

Abstract
Synthetic peptide-based serologic assays (Select-HTLV and SynthEIA) that distinguish the closely related human T-cell lymphotropic virus types I (HTLV-I) and II (HTLV-II) were tested blindly for their ability to correctly identify infection caused by either virus type. Of 57 HTLV-I and 38 HTLV-II specimens from individuals whose infections were confirmed by polymerase chain reaction, the Select-HTLV assay categorized 56 (98%) as HTLV-I, 36 (95%) as HTLV-II, and 3 (3%) as nontypeable. Similarly, the SynthEIA assay categorized 54 (95%) as HTLV-I, 29 (76%) as HTLV-II, and 12 (13%) as nontypeable. More importantly, no specimen was wrongly classified by either assay (100% specificity). Further, analysis of serial specimens from six patients also demonstrated concordant results with the PCR findings. Our results suggest that serotyping of HTLV infections can be achieved reliably by these peptide assays, thus the need for technically complex PCR-based HTLV typing, while not eliminated, can be greatly reduced.
AuthorsC R Roberts, R Mitra, K Hyams, S K Brodine, R B Lal
JournalJournal of medical virology (J Med Virol) Vol. 36 Issue 4 Pg. 298-302 (Apr 1992) ISSN: 0146-6615 [Print] United States
PMID1578221 (Publication Type: Journal Article)
Chemical References
  • Peptides
Topics
  • Base Sequence
  • Diagnosis, Differential
  • Enzyme-Linked Immunosorbent Assay
  • HTLV-I Infections (diagnosis)
  • HTLV-II Infections (diagnosis)
  • Human T-lymphotropic virus 1 (immunology)
  • Human T-lymphotropic virus 2 (immunology)
  • Humans
  • Molecular Sequence Data
  • Peptides (immunology)
  • Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Serologic Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: